Short Interest in Certara, Inc. (NASDAQ:CERT) Decreases By 7.5%

Certara, Inc. (NASDAQ:CERT) was the recipient of a large decrease in short interest during the month of November. As of November 15th, there was short interest totalling 4,960,000 shares, a decrease of 7.5% from the October 31st total of 5,360,000 shares. Currently, 4.5% of the shares of the stock are sold short. Based on an average daily volume of 1,300,000 shares, the short-interest ratio is currently 3.8 days.

Wall Street Analyst Weigh In

A number of brokerages recently commented on CERT. Barclays lowered their target price on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a research note on Thursday, November 7th. Robert W. Baird reduced their target price on shares of Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a report on Tuesday, November 5th. Finally, UBS Group raised shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 target price for the company in a report on Friday, September 27th. Six analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $15.92.

Insider Buying and Selling

In other news, insider Leif E. Pedersen sold 51,224 shares of Certara stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $11.29, for a total transaction of $578,318.96. Following the sale, the insider now owns 99,704 shares of the company’s stock, valued at approximately $1,125,658.16. The trade was a 33.94 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Patrick F. Smith sold 5,409 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $11.03, for a total value of $59,661.27. Following the completion of the sale, the insider now directly owns 50,091 shares in the company, valued at approximately $552,503.73. The trade was a 9.75 % decrease in their position. The disclosure for this sale can be found here. Insiders own 2.39% of the company’s stock.

Institutional Trading of Certara

Several hedge funds have recently bought and sold shares of the company. Blue Trust Inc. bought a new stake in shares of Certara during the 2nd quarter worth about $26,000. Innealta Capital LLC bought a new stake in shares of Certara during the 2nd quarter worth about $36,000. KBC Group NV raised its position in shares of Certara by 48.2% during the 3rd quarter. KBC Group NV now owns 4,873 shares of the company’s stock worth $57,000 after buying an additional 1,584 shares in the last quarter. Intech Investment Management LLC bought a new stake in shares of Certara during the 2nd quarter worth about $152,000. Finally, Algert Global LLC bought a new stake in shares of Certara during the 2nd quarter worth about $156,000. 73.96% of the stock is currently owned by institutional investors.

Certara Stock Down 3.3 %

CERT stock traded down $0.37 during mid-day trading on Wednesday, hitting $10.89. 1,181,280 shares of the company were exchanged, compared to its average volume of 809,777. The company has a market capitalization of $1.75 billion, a PE ratio of -56.30, a price-to-earnings-growth ratio of 5.71 and a beta of 1.53. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. Certara has a twelve month low of $9.41 and a twelve month high of $19.87. The firm has a fifty day simple moving average of $10.82 and a 200 day simple moving average of $12.94.

Certara (NASDAQ:CERT) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.11 by $0.02. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The business had revenue of $94.80 million during the quarter, compared to analyst estimates of $95.51 million. During the same period in the previous year, the business posted $0.06 EPS. The company’s quarterly revenue was up 10.7% on a year-over-year basis. On average, research analysts forecast that Certara will post 0.28 earnings per share for the current fiscal year.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.